Ying Yuan

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 83

Top Topics

Decision Making

Top Venues

Statistics in medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Ji Son, Yingao Zhang, Heather Y Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo, Natalie Clark, Robert Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M Johnson, Amadeo B Biter, Ying Yuan, Lauren P Cobb, David M Gershenson, Amir A Jazaeri, Karen H Lu, Pamela T Soliman, Shannon Neville Westin, Elizabeth D Euscher, Barrett C Lawson, Richard K Yang, Funda Meric-Bernstam, David S Hong
Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mengyi Lu, Ying Yuan, Suyu Liu
A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimes. Biostatistics (Oxford, England) (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter G Park, Vanessa Patrick, Fletcher A White
Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects. JMIR research protocols 13 (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Ji Son, Yingao Zhang, Heather Y Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo, Natalie Clark, Robert Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M Johnson, Amadeo B Biter, Ying Yuan, Lauren P Cobb, David M Gershenson, Amir A Jazaeri, Karen H Lu, Pamela T Soliman, Shannon Neville Westin, Elizabeth D Euscher, Barrett C Lawson, Richard K Yang, Funda Meric-Bernstam, David S Hong
Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter G Park, Vanessa Patrick, Fletcher A White
Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects. JMIR research protocols 13 (2024)
Liyun Jiang, Zhulin Yin, Fangrong Yan, Ying Yuan
MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities. Journal of immunotherapy and precision oncology 7 (3) (2024)
Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter G Park, Vanessa Patrick, Fletcher A White
Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects. JMIR research protocols 13 (2024)
Ying Yuan, Heng Zhou, Suyu Liu
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical trials (London, England) 21 (3) (2024)
Ying Yuan, Heng Zhou, Suyu Liu
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical trials (London, England) 21 (3) (2024)
Liyun Jiang, Zhulin Yin, Fangrong Yan, Ying Yuan
MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities. Journal of immunotherapy and precision oncology 7 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Rong-Ji Mu, Xiaojiang Zhan, Rui Sammi Tang, Ying Yuan
A Bayesian latent-subgroup platform design for dose optimization. Biometrics 80 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter G Park, Vanessa Patrick, Fletcher A White
Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects. JMIR research protocols 13 (2024)
Ying Yuan, Heng Zhou, Suyu Liu
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Ji Son, Yingao Zhang, Heather Y Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo, Natalie Clark, Robert Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M Johnson, Amadeo B Biter, Ying Yuan, Lauren P Cobb, David M Gershenson, Amir A Jazaeri, Karen H Lu, Pamela T Soliman, Shannon Neville Westin, Elizabeth D Euscher, Barrett C Lawson, Richard K Yang, Funda Meric-Bernstam, David S Hong
Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Ying Yuan, Heng Zhou, Suyu Liu
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical trials (London, England) (2024)
Timothy A Lin, Zachary Ryan McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal R Patel, Ramez Kouzy, Molly B El Alam, Alexander D Sherry, Sonal S Noticewala, Clifton David Fuller, Charles R Thomas, Ryan Sun, Jiun-Kae Jack Lee, Ruitao Lin, Ying Yuan, Yu Shyr, Tomer Meirson, Ethan Bernard Ludmir
Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ji Son, Yingao Zhang, Heather Y Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo, Natalie Clark, Robert Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M Johnson, Amadeo B Biter, Ying Yuan, Lauren P Cobb, David M Gershenson, Amir A Jazaeri, Karen H Lu, Pamela T Soliman, Shannon Neville Westin, Elizabeth D Euscher, Barrett C Lawson, Richard K Yang, Funda Meric-Bernstam, David S Hong
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Ji Son, Yingao Zhang, Heather Y Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo, Natalie Clark, Robert Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M Johnson, Amadeo B Biter, Ying Yuan, Lauren P Cobb, David M Gershenson, Amir A Jazaeri, Karen H Lu, Pamela T Soliman, Shannon Neville Westin, Elizabeth D Euscher, Barrett C Lawson, Richard K Yang, Funda Meric-Bernstam, David S Hong
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Anne-Marie Chaftari, Hiba Dagher, Ray Hachem, Ying Jiang, Peter Lamie, Rita Wilson Dib, Teny M John, Andrea Haddad, Ann Philip, Shahnoor Alii, Patricia Mulanovich, Ying Yuan, Patrick Chaftari, Issam I Raad
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. The Journal of antimicrobial chemotherapy (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Kanwal P S Raghav, Edmund S Kopetz, Ying Yuan
Reply to Y. Yu et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (7) (2023)
Timothy A Gregory, Maximilian Mastall, Heather Lin, Kenneth R Hess, Ying Yuan, Manuela Martin-Bejarano Garcia, Gregory N Fuller, Kristin D Alfaro, Maria K Gule-Monroe, Jason T Huse, Soumen Khatua, Ganesh Rao, David I Sandberg, Jeffrey S Wefel, Debra N Yeboa, Arnold C Paulino, Susan L McGovern, Wafik Zaky, Anita Mahajan, Dima Suki, Shiao-Pei Weathers, Rebecca A Harrison, John F de Groot, Vinay K Puduvalli, Marta Penas-Prado, Nazanin K Majd
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neuro-oncology advances 5 (1) (2023)
Liyun Jiang, Peter F Thall, Fangrong Yan, Scott Kopetz, Ying Yuan
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical trials (London, England) (2023)
Peter F Thall, Yong Zang, Ying Yuan
Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical statistics (2023)
Kanwal P S Raghav, Edmund S Kopetz, Ying Yuan
Reply to Y. Yu et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (7) (2023)
Peter F Thall, Yong Zang, Andrew Genius Chapple, Ying Yuan, Ruitao Lin, David Marin, Pavlos Msaouel
Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Kanwal P S Raghav, Edmund S Kopetz, Ying Yuan
Reply to Y. Yu et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (7) (2023)
Yujie Zhao, Daniel Li, Rong Liu, Ying Yuan
Bayesian optimal phase II designs with dual-criterion decision making. Pharmaceutical statistics (2023)
Kanwal P S Raghav, Edmund S Kopetz, Ying Yuan
Reply to Y. Yu et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Beibei Guo, Ying Yuan
DROID: Dose-ranging approach to optimizing dose in oncology drug development. Biometrics (2023)
Peng Yang, Shawna M Hubert, P Andrew Futreal, Xingzhi Song, Jianhua Zhang, J Jack Lee, Ignacio Wistuba, Ying Yuan, Jianjun Zhang, Ziyi Li
A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. bioRxiv : the preprint server for biology (2023)
Wen Zhang, Glen Laird, Josh Chen, Ying Yuan
A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Statistics in medicine (2023)
Peng Yang, Yuansong Zhao, Lei Nie, Jonathon Vallejo, Ying Yuan
SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Biometrics (2023)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer research communications (2023)
Beibei Guo, Ying Yuan
DROID: dose-ranging approach to optimizing dose in oncology drug development. Biometrics (2023)
Yixuan Zhao, Ying Yuan, Edward L Korn, Boris Freidlin
Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Timothy A Gregory, Maximilian Mastall, Heather Lin, Kenneth R Hess, Ying Yuan, Manuela Martin-Bejarano Garcia, Gregory N Fuller, Kristin D Alfaro, Maria K Gule-Monroe, Jason T Huse, Soumen Khatua, Ganesh Rao, David I Sandberg, Jeffrey S Wefel, Debra N Yeboa, Arnold C Paulino, Susan L McGovern, Wafik Zaky, Anita Mahajan, Dima Suki, Shiao-Pei Weathers, Rebecca A Harrison, John F de Groot, Vinay K Puduvalli, Marta Penas-Prado, Nazanin K Majd
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neuro-oncology advances 5 (1) (2023)
Timothy A Gregory, Maximilian Mastall, Heather Lin, Kenneth R Hess, Ying Yuan, Manuela Martin-Bejarano Garcia, Gregory N Fuller, Kristin D Alfaro, Maria K Gule-Monroe, Jason T Huse, Soumen Khatua, Ganesh Rao, David I Sandberg, Jeffrey S Wefel, Debra N Yeboa, Arnold C Paulino, Susan L McGovern, Wafik Zaky, Anita Mahajan, Dima Suki, Shiao-Pei Weathers, Rebecca A Harrison, John F de Groot, Vinay K Puduvalli, Marta Penas-Prado, Nazanin K Majd
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neuro-oncology advances 5 (1) (2023)
Benjamin Garmezy, Jinesh S Gheeya, Heather Y Lin, Yuefan Huang, Taebeom Kim, Xian-Li Jiang, Kyaw Zin Thein, Patrick G Pilié, Fadl Zeineddine, Wanlin Wang, Kenna Rael Shaw, Jordi Rodon Ahnert, John Paul Shen, Ying Yuan, Funda Meric-Bernstam, Ken Chen, Timothy A Yap
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO precision oncology 6 (2022)
Anne-Marie Chaftari, Ray Hachem, Alexandre E Malek, Victor E Mulanovich, Ariel D Szvalb, Ying Jiang, Ying Yuan, Shahnoor Ali, Rita Deeba, Patrick Chaftari, Issam I Raad
A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open forum infectious diseases 9 (6) (2022)
Michael E Scheurer, Renke Zhou, Mark R Gilbert, Melissa L Bondy, Erik P Sulman, Ying Yuan, Yanhong Liu, Elizabeth Vera, Merideth M Wendland, Emad F Youssef, Volker W Stieber, Ritsuko R Komaki, John C Flickinger, Lawrence C Kenyon, H Ian Robins, Grant K Hunter, Ian R Crocker, Samuel T Chao, Stephanie L Pugh, Terri S Armstrong
Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-oncology advances 4 (1) (2022)
Yun Qing, Peter F Thall, Ying Yuan
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical statistics (2022)
Yanhong Zhou, Yujie Zhao, Greg Cicconetti, Yunming Mu, Ying Yuan, Li Wang, Sudhir Penugonda, Zeena Salman
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharmaceutical statistics (2022)
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca Ann Previs, Anthony D Elias, Richard D Carvajal, Thomas J George, Ying Yuan, Lihou Yu, Shannon Neville Westin, Yan Xing, Ecaterina E Ileana Dumbrava, Daniel D Karp, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Jordi Rodon Ahnert, Naoko Takebe, Karen H Lu, Khandan Keyomarsi, Funda Meric-Bernstam
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Yanhong Zhou, Ruitao Lin, J Jack Lee, Daniel Li, Li Wang, Ruobing Li, Ying Yuan
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in medicine 41 (11) (2022)
Yujie Zhao, Rui Sammi Tang, Yeting Du, Ying Yuan
A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics (2022)
Ying Yuan, Yixuan Zhao
Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Statistics in medicine 41 (27) (2022)
Ying Yuan, Jing Wu, Mark R Gilbert
BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neuro-oncology practice 8 (6) (2021)
Liyun Jiang, Lei Nie, Ying Yuan
Elastic priors to dynamically borrow information from historical data in clinical trials. Biometrics (2021)
Lynette M Phillips, Shoudong Li, Joy Gumin, Marc Daou, Daniel Ledbetter, Jing Yang, Sanjay Singh, Brittany C Parker Kerrigan, Anwar Hossain, Ying Yuan, Candelaria Gomez-Manzano, Juan Fueyo, Frederick F Lang
An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro-oncology 23 (11) (2021)
Rong-Ji Mu, Jin Xu, Rui Sammi Tang, Scott Kopetz, Ying Yuan
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Statistics in medicine (2021)
Alexander V Prokhorov, Karen Sue Calabro, Ashish Arya, Sophia Russell, Katarzyna W Czerniak, Gabrielle C Botello, Minxing Chen, Ying Yuan, Adriana Pérez, Damon J Vidrine, Cheryl L Perry, Georges Elias Khalil
Mobile Text Messaging for Tobacco Risk Communication Among Young Adult Community College Students: Randomized Trial of Project Debunk. JMIR mHealth and uHealth 9 (11) (2021)
Jing Pan, Yue Tan, Guoling Wang, Biping Deng, Zhuojun Ling, Weiliang Song, Samuel Seery, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Ying Yuan, Fangrong Yan, Zhenglong Tian, Kaiting Tang, Jiecheng Zhang, Alex H Chang, Xiaoming Feng
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (30) (2021)
Yanhong Zhou, Jiun-Kae Jack Lee, Shunguang Wang, Stuart Bailey, Ying Yuan
Incorporating historical information to improve phase I clinical trials. Pharmaceutical statistics 20 (6) (2021)
Haolun Shi, Jiguo Cao, Ying Yuan, Ruitao Lin
uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in medicine 40 (11) (2021)
Nazanin K Majd, Maximilan Mastall, Heather Lin, Seyede Shiva Dibaj, Kenneth R Hess, Ying Yuan, Manuela Martin-Bejarano Garcia, Gregory N Fuller, Kristin D Alfaro, Maria K Gule-Monroe, Jason T Huse, Soumen Khatua, Ganesh Rao, David I Sandberg, Jeffrey S Wefel, Debra N Yeboa, Arnold C Paulino, Susan L McGovern, Wafik Zaky, Anita Mahajan, Dima Suki, Shiao-Pei Weathers, Rebecca A Harriso, John F De Groo, Vinay K Puduvalli, Marta Penas-Prado
Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-oncology advances 3 (1) (2021)
Yeonhee Park, Suyu Liu, Peter F Thall, Ying Yuan
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics (2021)
Daniel Kang, Christopher S Coffey, Brian J Smith, Ying Yuan, Qian Shi, Jun Yin
Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Statistics in medicine 40 (12) (2021)
Yeonhee Park, Ying Yuan, Jing Ning, Suyu Liu, Ziding Feng
Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in medicine 40 (8) (2021)
Yimei Li, Ying Yuan
PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics 76 (4) (2020)
Ruitao Lin, Yanhong Zhou, Fangrong Yan, Daniel Li, Ying Yuan
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO precision oncology 4 (2020)
Yanhong Zhou, J Jack Lee, Ying Yuan
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Statistics in medicine 38 (28) (2019)
Ruitao Lin, Peter F Thall, Ying Yuan
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76 (1) (2019)
Heng Zhou, Thomas A Murray, Haitao Pan, Ying Yuan
Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in medicine 37 (14) (2018)
Rui Sammi Tang, Jing Shen, Ying Yuan
ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Statistics in medicine 38 (7) (2018)
Thomas A Murray, Ying Yuan, Peter F Thall, Joan H Elizondo, Wayne L Hofstetter
A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74 (3) (2018)
Weining Shen, Jing Ning, Ying Yuan, Anna S Lok, Ziding Feng
Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74 (1) (2017)